HealthDay on MSN2h
Some GLP-1s Achieve More Weight Loss Than Others: StudyThree GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been ap ...
The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...
Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...
According to the study, participants taking Zepbound lost an average of 20.2% of their starting weight after 72 weeks, ...
Novo's drug candidate, CagriSema, showed weight loss below expectations during a trial, dealing a blow to the company's plans ...
Study finds GLP-1 medications such as Ozempic could result in cuts to grocery spending and reductions in spending at ...
Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...
This top healthcare company trades at 13 times forward earnings. It has a diverse portfolio of products, yields 3.6% at the ...
The rise of GLP-1 medications has transformed the way Americans lose weight, and the data supports that ... some GLP-1 medications like Wegovy and Zepbound are FDA-approved for weight loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback